Overcoming breast cancer heterogeneity and resistance using a novel therapeutic approach targeting the metastasis suppressor NDRG1.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1140447

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Breast cancer (BrCa) is the leading cause of cancer death in women and current treatments suffer from development of resistance, leading to metastatic progression. I will assess a novel treatment strategy for BrCa, targeting a gene that is able to inhibit multiple key drivers of BrCa, using a novel potent and selective anti-cancer agent. This approach has the potential to overcome resistance to current therapies and alleviate the onset of metastasis, to improve prognosis for BrCa patients.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2022

Funding Scheme: Career Development Fellowships

Funding Amount: $431,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmaceutical Sciences

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biochemistry | cell biology | pharmacology | therapeutic agents | therapeutic target

Related Links